الفهرس 
Role of CD10 marker in differentiating malignant thyroid neoplasms from benign thyroid lesions Immunohistochemical & Histopathological study
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 179 |  |  |
| | | from | 179 | | |
Abstract
Aim of the work: The aim of this work is to study the immunohistochemical expression of CD10 in malignant thyroid neoplasms and different benign lesions and assess whether CD10 can be used as a malignancy marker in thyroid pathology. Methods: Eighty-three total & hemithyroidectomy specimens; collected from the Pathology Department, Faculty of Medicine, Cairo University. Two slides were prepared from each paraffin embedded tumor block, one slide was stained for Hematoxylin and eosin (H & E) staining for histopathological reassessment and the other positively charged slide was stained immunohistochemically by CD10 monoclonal antibody. The immunohistochemical demonstration of the immunohistochemical marker was accomplished by using immunoperoxidase method. Brown cytoplasmic with or without membrane staining was considered positive expression. A semi-quantitative scoring based on the percentage of positive cells was performed. Results: Ninety-one percent of studied malignant cases showed positive CD10 expression while 58% of benign cases showed positive CD10 expression indicating a significant correlation between both categories (benign and malignant) and CD10 immunohistochemical expression (P value= 0.000). No significant correlation between CD10 immunohistochemical expression and patients’ age, sex, pathologic T stage, positive lymph node metastasis and multifocality could be detected. Conclusion:The results of the current study indicate that due to the higher expression of CD10 in malignant thyroid neoplasms than benign thyroid lesions, it might be used for differentiating mentioned lesions